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Abstract
Background: Monitoring systemic inflammatory activity during steroid therapy of canine immune-
mediated polyarthritis (IMPA) is difficult and mainly relies on clinical signs.
Case presentation: Canine serum C-reactive protein (CRP) was measured serially and blinded
during a 27-week follow-up period of a case of Anaplasma phagocytophilia induced type II immune-
mediated polyarthritis.
Conclusion: WBC was, as expected, observed not to reflect the inflammatory activity during
steroid treatment in a clinical useful manner, whereas, CRP is suggested a valuable unbiased marker
of inflammatory activity during steroid treatment in this case.
Background
Monitoring systemic inflammatory activity during steroid
therapy of canine immune-mediated diseases may be dif-
ficult. The clinician mainly has to rely on clinical signs [1]
since objective fast-reacting inflammatory markers (white
blood cell count [WBC] and absolute numbers of granu-
locytes) usually are so affected by the steroid treatment per
se [2] that they are inadequate for reliable monitoring.
Thus, a fast-reacting objective inflammatory marker not
biased by steroids could potentially be of clinical value.
One such marker could be canine C-reactive protein
(CRP). Studies on canine CRP reported clinical applicabil-
ity for monitoring variation in inflammatory activity dur-
ing various stages of disease [3,4], assessing therapy
efficiency[4,5] and was reported to be unbiased by corti-
costeroids[6,7]. Furthermore, validated assays for measur-
ing canine CRP are commercially available [8-10]. This
report describes a case of canine type II IMPA that was
monitored blinded in the follow-up period using serial
measurements of canine serum CRP concentration.
Case report
Diagnosis
A 9-year old, female English Springer Spaniel was referred
to the Small Animal Veterinary Teaching Hospital,
Department of Small Animal Clinical Sciences, The Royal
Veterinary and Agricultural University, Denmark with a
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history of weight-loss, lethargy, intermittent lameness,
generalised lymphadenopathy and recurrent febrile epi-
sodes during the preceding 8 weeks despite antibiotic and
anti-inflammatory steroid treatment. Clinical investiga-
tion revealed depression, pyrexia (39.9°C), lameness,
reluctance to stand and joint pain in multiple joints. Diag-
nostic procedures included complete blood count (CBC),
blood smear analysis, serum biochemistry, urinalysis,
cytological evaluation of lymph nodes and synovial fluid
and radiographs of joints. The CBC, blood smear and
serum biochemistry revealed a regenerative anaemia char-
acterised by increased reticulocyte count, spherocytosis
and erythrocyte autoagglutination. Cytology revealed
reactive lymphadenopathy in lymph notes and neu-
trophilic inflammation in all joints sampled, with Ana-
plasma phagocytophilum-like inclusions in occasional
neutrophils. Radiographs revealed no sign of erosive
joint-processes with only slight soft tissue changes. A diag-
nosis of type II Immune-mediated polyarthritis (IMPA)
and immune-mediated haemolytic anaemia (IMHA) was
established and antibiotic therapy (doxycycline 10 mg/kg
sid [Ronaxan; Merial]) was initiated. To further confirm A.
phagocytophilum infection and rule out other potential sus-
pect causes of IMHA and type II IMPA, thoracic radio-
graphs, abdominal ultrasound, PCR tests for canine
distemper virus, Ehrlichia spp., serum antibody titer-tests
for Borrelia spp., Bartonella spp. and Babesia spp. and anti-
nuclear antibody test were performed. All were unremark-
able. A serum antibody titer for Ehrlichia equi (Anaplasma
phagocytophilum  [11]) was, however, positive (IgG titer
1:640 [cut-off; 1:32]). Based on the clinical and paraclini-
cal examinations, the dog was considered to suffer from
IMHA and a type II IMPA secondary to an A. phagocy-
tophilum infection.
Immunosuppressive therapy (prednisolone 1.0 mg/kg bid
[Prednisolonacetat; Nycomed]) was initiated and antibi-
otic therapy (doxycycline 10 mg/kg sid) was continued.
Follow-up
In the follow-up period, the dog was monitored by means
of clinical examinations and CBC on a weekly to bi-
weekly schedule. C-reactive protein were measured by
means of a validated human CRP immunoturbidimetric
assay [8,12] in parallel with CBC. The CRP values were not
disclosed to the clinicians (blinded). The corticosteroid
dosage was attempted titrated to an acceptable clinical
outcome regarding symptoms of the IMPA and adverse
effects of therapy (Fig. 1). The dog had several periods
with relapse of clinical symptoms of polyarthritis (Fig. 1)
mainly in relation to tapering of the corticosteroid ther-
apy. Azathioprine (2.0 mg/kg/day [Imurel; Glaxo Well-
come]) was included in the therapy regimen from day 105
in combination with prednisolone to possibly lower the
necessary dose of prednisolone (clinical signs of steroid
associated adverse effects [polyuria, polydipsia, panting
and Cushingoid appearence] were observed at the dosage
needed for sufficient IMPA suppression). For 38 days no
clinical signs of IMPA were observed on a combination of
prednisolone (0.125-0.5 mg/kg bid) and azathioprine
(2.0 mg/kg sid), with acceptable degrees of adverse effects
at the lower doses of prednisolone. Symptoms of IMPA
returned at day 143. Bone marrow suppression with pan-
leukopenia (WBC<6.5·109/L) (Fig. 1) and thrombocyto-
penia (Thrombocyte count<200·109/L) was observed at
day 170, where the azathioprine dosage was halved and
later discontinued at day 180. The dog was euthanized at
day 189 as the owner declined further therapy. Necropsy
was not performed, due to owner's reluctance. The WBC
and neutrophil count were abnormally high from initia-
tion of therapy until day 144 and 158, respectively and
decreased to leukopenic and neutropenic (<3.2·109/L)
levels at day 170. The observed fluctuations of the WBC
paralleled the fluctuations of the neutrophil count very
closely and the data are therefore not shown. Both param-
eters did not reflect the clinical signs of disease activity in
a manner useful for treatment decisions (see neutrophil
count in fig. 1).
CRP variations during therapy
High CRP concentrations (local reference interval 0–18
mg/L) were observed at day 0–4 (65–66 mg/L) declining
to within reference interval during initial high-dose pred-
nisolone treatment (0.5–1.0 mg/kg bid [day 5–30]) (Fig.
1). From day 30 to day 90 (with prednisolone dosage con-
sistently below 0.5 mg/kg bid) CRP gradually increased.
The CRP was already increased at the first relapses of clin-
Neutrophil count [], serum C-reactive protein concentra- tions (CRP [● ]) and daily dosages of prednisolone [▲ ] in a  dog with type II immune-mediated polyarthritis plotted  against days after referral of patient Figure 1
Neutrophil count [], serum C-reactive protein concentra-
tions (CRP [● ]) and daily dosages of prednisolone [▲ ] in a 
dog with type II immune-mediated polyarthritis plotted 
against days after referral of patient. Shaded areas are peri-
ods with clinical symptoms of polyarthritis.Acta Veterinaria Scandinavica 2006, 48:9 http://www.actavetscand.com/content/48/1/9
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ical signs of polyarthritis (day 47–49 and day 61–95) and
CRP was persistently high during the periods of clinical
signs. An equivalent pattern was observed during the sec-
ond phase of prednisolone titration with a rapid decline
in CRP during high prednisolone dosage and an increase
shortly after tapering the dosage, with observation of a
high CRP value at the relapse of clinical signs (day 143–
160) (Fig. 1). The CRP declined to immeasurable values
during the period of severe bone marrow suppression,
where inflammatory activity was impaired by a depletion
of inflammatory cells.
Thus, a marked increase in CRP were observed on two
occasions, related to the reappearence of clinical signs of
polyarthritis.
Discussion
Infections of Ehrlichia spp. (Anaplasma spp.) were reported
as a cause of type II IMPA in dogs [13] where it is assumed
that the infectious process provides an antigenic source
for immune complex formation, and either the antigen or
circulating complexes are deposited within the synovium
to initiate inflammation by a type III hypersensitivity reac-
tion [14]. The involvement of A. phagocytophilum in the
present diagnosis was based on clinical signs, cytological
findings and a positive antibody titer against Ehrlichia equi
(A. phagocytophilum [11]), but a negative PCR for Ehrlichia
spp. antigen was also obtained. However, negative PCR
was reported to be common even after short antibiotic
treatment [15].
In general, the therapeutic regimen of type II IMPA is
directed against the infectious agent, where recovery can
be seen upon clearance of the infectious agent [1,13].
However, supportive immunosuppressive therapy is often
part of the regimen to help resolve the joint inflamma-
tion, using either prednisolone alone or in combination
with cytotoxic drugs [1]. When clinical signs of polyarthri-
tis have resolved, the dosages are gradually reduced and if
signs return the dosage is increased [1].
The observations made in the present case suggest that
serial measurements of CRP during immunosuppressive
therapy of canine type II IMPA could be useful as an objec-
tive marker of inflammatory activity. This could have a
positive effect on case management of type II IMPA by
possibly enabling early assessment of treatment efficiency
and detection of undesirable inflammatory activity, unbi-
ased by treatment. C-reactive protein is non-specific,
regarding the cause of inflammation. Thus, a decrease in
concentration during treatment indicates a general down-
regulation of inflammatory activity[3-5,16]. Whereas, an
increase in CRP concentration during treatment indicates
increased inflammatory activity [3,4,17], due to increased
disease activity or presence of other secondary stimulus
(both information of clinical importance). Finally, canine
CRP was reported not to be biased as a marker of inflam-
matory activity by neither steroid nor non-steroid drugs
[6,7,18]. The WBC and neutrophil count in the present
case were, however, adversely biased as inflammatory
markers by the steroid treatment, as would be expected
[2], and thus, the observed fluctuations of WBC and neu-
trophil count were not reflecting disease activity in a clin-
ical useful manner. Canine serum CRP has earlier been
studied as a marker of disease-activity in osteoarthritis
(OA) [19], where only slightly elevated levels were
observed. However, a marked difference between the CRP
levels in a localized process (as OA [21]) and a generalized
inflammatory disease (as IMPA in the present case), is
expected, as CRP is a marker of systemic inflammation
(produced in the liver upon stimulation by an increased
level of circulating pro-inflammatory cytokines[20]).
In conclusion, CRP measurements seemed potentially val-
uable as an unbiased marker of the inflammatory activity
during immunosuppressive treatment of type II IMPA in
the present case, seemingly providing clinically useful
information superior to that of CBC and clinical observa-
tions. Further studies should be conducted to investigate
the general applicability of CRP as an unbiased marker of
inflammatory activity during treatment of IMPA.
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